Merck opens Bio-devel­op­ment cen­tre in Shang­hai

BioSpectrum (Asia) - - Company News -

Merck, a lead­ing science and tech­nol­ogy com­pany, an­nounced the open­ing of its first BioReliance End-to-End Biode­vel­op­ment Cen­tre in the Asia Pa­cific (APAC) re­gion. Lo­cated in Shang­hai, China, the cen­ter will pro­vide a full range of process devel­op­ment ca­pa­bil­i­ties and ser­vices, in­clud­ing cell line devel­op­ment, up­stream and down­stream process devel­op­ment and non-GMP clin­i­cal pro­duc­tion.

The Shang­hai cen­tre is de­signed to meet the spe­cific needs of cus­tomers in the APAC re­gion. Staffed by lo­cal process sci­en­tists and en­gi­neers, the cen­ter will pro­vide an in­te­grated suite of ser­vices for bio­phar­ma­ceu­ti­cal com­pa­nies in China and across APAC to ac­cel­er­ate clin­i­cal drug devel­op­ment from mol­e­cule to com­mer­cial pro­duc­tion. Cus­tomers will get full sup­port, not only with process devel­op­ment or pro­duc­tion, but also with reg­u­la­tory, qual­ity and train­ing.

This new in­vest­ment in China marks an­other mile­stone for Merck in one of Asia’s most dy­namic biotech mar­kets. In Novem­ber 2016, Merck an­nounced a €250 mil­lion pro­duc­tion value chain in­vest­ment in Nan­tong, ded­i­cated to both the pro­duc­tion of phar­ma­ceu­ti­cals on China’s Essen­tial Drug List and the man­u­fac­ture of a range of in­no­va­tive prod­ucts and ser­vices for the pharma, bio­pharma and life sci­ences in­dus­tries.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.